With CAGR of 7.84%, Lung Cancer Diagnostics Market Size and Forecast 2021 to 2027

WILMINGTON, Del. - Oct. 28, 2022 - PRLog -- Lung cancer is life threatening lung tumour characterised by uncontrolled growth of cell in lung tissues. Smoking cigarette is chief risk factor for growth of lung cancer. Prolonged contact with tobacco smoke can also lead to lung cancer. The diagnosis of lung cancer is authenticated by biopsy which is done with the help of bronchoscopy or CT-guidance. The treatment of lung cancer can done by chemotherapy, radiotherapy, immunotherapy, surgery etc. As per the report issued by WHO, the cancer is leading cause of death worldwide, there are nearly 10 million deaths in 2020 in which 2.21 million deaths are occurred due to lung cancer only.

MARKET DYNAMICS- LUNG CANCER DIAGNOSTIC MARKET

The lung cancer diagnostic market is anticipated to grow at CAGR of 7.84% during the forecast period of 2021 to 2027.  The rising awareness regarding about lung cancer and government regulation for prevention of smoking is also contributing in the growth of lung cancer diagnostic market. The dynamic factors such as rise in number of early smokers is propelling growth of lung cancer diagnostic market. The increasing product launches is also boosting growth of lung cancer diagnostic market. However, high cost of diagnosis is hindering the growth of lung cancer diagnostic market.

LUNG CANCER DIAGNOSTIC MARKET- SEGMENTAL OVERVIEW

The lung cancer diagnostic market (https://www.axiommrc.com/product/10847-lung-cancer-diagno...) is segmented into cancer type, diagnostic test, end user and geography.

LUNG CANCER DIAGNOSTIC MARKET BY CANCER TYPE

The lung cancer diagnostic market is comprised of cancer type such as small cell lung cancer and non-small cell lung cancer.

LUNG CANCER DIAGNOSTIC MARKET BY DIAGNOSTIC TEST

The lung cancer diagnostic market is comprised of diagnostic test such as biomarkers test, imaging test, biopsy and other tests. The biomarkers test is sub-categorised into the CA test, HER2 Test, ALK Test, Angiogenesis Inhibitors, KRAS mutation test.

LUNG CANCER DIAGNOSTIC MARKET BY END USER

The lung cancer diagnostic market is comprised of end user such as hospital assisted labs, independent diagnostic laboratories and cancer research institutes.

KEY PLAYERS IN LUNG CANCER DIAGNOSTIC MARKET

The major key players operating in the lung cancer diagnostic market are Illumina Inc., Abbott, Thermo Fisher Scientific Inc., Qiagen, Quest Diagnostics Incorporated, Neogenomics, Nanostring Technologies Inc, Myriad Genetics Inc, Roche Holding Ag, Danaher, Agilent Technologies, Astrazeneca, Sanofi, Janssen Pharmaceuticals, Biomérieux Sa, Ge Healthcare, Hologic, Koninklijke Philips N.V, Biotheranostics and Exact Sciences among others.

Get Sample Copy of this Research: https://www.axiommrc.com/request-for-sample/10847-lung-cancer-diagnostic-market-report